The addition of erythropoiesis-stimulating agents (ESA) such as recombinant erythropoietin (rEPO), may be beneficial based on retrospective data, especially when there is (relative) reticulocytopenia (57). This evidence concerns the gene EPO and Reticulocytopenia.